Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46,239,275
-
Total 13F shares
-
17,724,118
-
Share change
-
+4,503,568
-
Total reported value
-
$248,330,352
-
Put/Call ratio
-
64%
-
Price per share
-
$14.01
-
Number of holders
-
100
-
Value change
-
+$65,704,038
-
Number of buys
-
58
-
Number of sells
-
29
Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q3 2023
As of 30 Sep 2023 UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) had 100 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 17,724,118 shares of stock of the company.
Largest 10 holders included GREAT POINT PARTNERS LLC, MENORA MIVTACHIM HOLDINGS LTD., RA CAPITAL MANAGEMENT, L.P., BlackRock Inc., CREDIT SUISSE AG/, Harel Insurance Investments & Financial Services Ltd., RTW INVESTMENTS, LP, Migdal Insurance & Financial Holdings Ltd., SILVERARC CAPITAL MANAGEMENT, LLC, and Wildcat Capital Management, LLC.
This table shows 100 institutional shareholders of the security as of 30 Sep 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.